Antibody-drug conjugate · Cytotoxic, directed at tissue factor (F3) · developed by Sutro Biopharma
STRO-004 is an antibody-drug conjugate in which an Fc-silent IgG1 antibody against tissue factor (F3) is linked to the topoisomerase I inhibitor exatecan. After binding TF on tumor cells and internalization, exatecan is released, causing DNA damage and apoptosis, and it also kills neighboring TF-negative cells. It is studied in head and neck, lung, esophageal, gastric, colorectal, pancreatic, cervical, endometrial and urothelial cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07227168 | Phase 1 | Head and Neck Squamous Cell Carcinoma HNSCC | Recruiting | STRO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cervical CancerColorectal CancerEndometrial CancerEsophageal CancerGastric CancerHead and Neck Squamous Cell Carcinoma HNSCCNon-Small Cell Lung Cancer NSCLCPancreatic Ductal Adenocarcinoma (PDAC)Urothelial Cancer
See STRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
STRO catalysts and pipeline →